Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited (ASX: ACW) has requested an immediate trading halt on its securities, pending the release of results from its XanaCIDD phase 2a clinical trial. The halt will remain in effect until the market announcement is made or until the commencement of normal trading on Monday, 12 August 2024, whichever is earlier. This strategic move ensures that all investors have access to material information simultaneously.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
